GlycoMimetics Statistics
Total Valuation
GlycoMimetics has a market cap or net worth of $17.33 million. The enterprise value is -$13.32 million.
| Market Cap | 17.33M |
| Enterprise Value | -13.32M |
Important Dates
The next estimated earnings date is Wednesday, July 31, 2024, before market open.
| Earnings Date | Jul 31, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
GlycoMimetics has 64.46 million shares outstanding. The number of shares has increased by 6.81% in one year.
| Shares Outstanding | 64.46M |
| Shares Change (YoY) | +6.81% |
| Shares Change (QoQ) | +0.10% |
| Owned by Insiders (%) | 3.58% |
| Owned by Institutions (%) | 51.81% |
| Float | 40.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,732.80 |
| Forward PS | n/a |
| PB Ratio | 0.60 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.28, with a Debt / Equity ratio of 0.02.
| Current Ratio | 6.28 |
| Quick Ratio | n/a |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -88.40% and return on invested capital (ROIC) is -133.54%.
| Return on Equity (ROE) | -88.40% |
| Return on Assets (ROA) | -76.60% |
| Return on Capital (ROIC) | -133.54% |
| Revenue Per Employee | $286 |
| Profits Per Employee | -$1.07M |
| Employee Count | 35 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -84.46% in the last 52 weeks. The beta is 2.14, so GlycoMimetics's price volatility has been higher than the market average.
| Beta (5Y) | 2.14 |
| 52-Week Price Change | -84.46% |
| 50-Day Moving Average | 0.57 |
| 200-Day Moving Average | 1.81 |
| Relative Strength Index (RSI) | 36.67 |
| Average Volume (20 Days) | 8,994,827 |
Short Selling Information
The latest short interest is 1.76 million, so 2.74% of the outstanding shares have been sold short.
| Short Interest | 1.76M |
| Short Previous Month | 2.09M |
| Short % of Shares Out | 2.74% |
| Short % of Float | 4.40% |
| Short Ratio (days to cover) | 1.63 |
Income Statement
In the last 12 months, GlycoMimetics had revenue of $10,000 and -$37.28 million in losses. Loss per share was -$0.58.
| Revenue | 10,000 |
| Gross Profit | 10,000 |
| Operating Income | -39.45M |
| Pretax Income | -37.28M |
| Net Income | -37.28M |
| EBITDA | -36.35M |
| EBIT | -37.28M |
| Loss Per Share | -$0.58 |
Balance Sheet
The company has $31.28 million in cash and $630,827 in debt, giving a net cash position of $30.65 million or $0.48 per share.
| Cash & Cash Equivalents | 31.28M |
| Total Debt | 630,827 |
| Net Cash | 30.65M |
| Net Cash Per Share | $0.48 |
| Equity (Book Value) | 28.91M |
| Book Value Per Share | 0.45 |
| Working Capital | 27.97M |
Cash Flow
In the last 12 months, operating cash flow was -$33.78 million and capital expenditures -$26,636, giving a free cash flow of -$33.81 million.
| Operating Cash Flow | -33.78M |
| Capital Expenditures | -26,636 |
| Free Cash Flow | -33.81M |
| FCF Per Share | -$0.53 |
Margins
Gross margin is 100.00%, with operating and profit margins of -394,493.02% and -372,767.37%.
| Gross Margin | 100.00% |
| Operating Margin | -394,493.02% |
| Pretax Margin | -372,767.37% |
| Profit Margin | -372,767.37% |
| EBITDA Margin | -363,459.65% |
| EBIT Margin | -372,767.37% |
| FCF Margin | -338,085.09% |
Dividends & Yields
GlycoMimetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.81% |
| Shareholder Yield | -6.81% |
| Earnings Yield | -215.12% |
| FCF Yield | -195.11% |
Analyst Forecast
The average price target for GlycoMimetics is $12.00, which is 4,364.29% higher than the current price. The consensus rating is "Buy".
| Price Target | $12.00 |
| Price Target Difference | 4,364.29% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 404.16% |
| EPS Growth Forecast (5Y) | -24.45% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GlycoMimetics has an Altman Z-Score of -19.77 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -19.77 |
| Piotroski F-Score | 1 |